標的検証
We offer multi-validation solutions for preclinical targets across numerous therapeutic fields
Target validation evaluates the druggability of an identified target. It does this by assessing key biological features of a target to estimate whether an investigational drug is likely to elicit a therapeutic benefit within an acceptable safety window. Having a well-researched target reduces the risk of failure during the later stages of development.
Several important features will determine whether a target is druggable. This includes a target’s regular function in maintaining cell physiology, its involvement and modulation in disease pathophysiology, as well as its localization and distribution across tissues or cells.
Ultimately, target validation provides researchers with a biologically sound, and clinically relevant, rationale that warrants further investigation and investment. Through our integrated program, InnoSer scientists continuously relay insights towards the later stages of drug development. This helps to minimize risks and to have the most seamless and efficient experience possible.
私たちのアプローチ
We provide (custom) assay development, execution, analysis and reporting.
If needed, we can source and validate your specific required research models at our facilities. Having established close connections to many (academic) hospitals and academic research groups in the Benelux, we can source primary patient materials on demand for made-to-measure, co-development projects.
These methods are important to help provide trust in your compounds throughout the development process. With InnoSer’s combination of readout possibilities and expertise we allow drug developers to build an insightful dossier and mitigate development risks early on.
治療薬開発を推進するため、専門家と提携しましょう。
当社のチームと協力し、精密かつ専門的な知見をもって、貴社の薬剤と治療標的の効果を評価します
当社の能力
Pharmacometrics tools can help assess the feasibility of targets and drugs. By integrating data from various pharmaceutical databases we can help to extrapolate pharmacokinetic profiles of prospective approaches across in-vitro and in-vivo situations (IVIVE).
InnoSer can co-validate your target in relevant biological contexts.
Through our access to primary clinical samples from our clinical network, we can help you to investigate your target in healthy and diseased clinical subjects. In addition, we support you in validating and selecting the most suitable preclinical disease models that provide excellent translatability of pathophysiology.
Target validation models
- Cell lines of health and disease
- Transgenic lines
- Primary cell material of health and disease
- Ex vivo models of health and disease
- In vivo models
- Custom model development
Readouts
- In silico modelling
- Gene and protein expression
- Histopathology
- Blood biomarker analysis
- Immune cell profiling via flow cytometry
- High content cellular imaging
- Ex vivo imaging
- Multi-immune fluorescence
- Biomarker identification and validation
- Multiplex assays (Meso-Scale Discovery)
医薬品開発パイプラインのナビゲーション
AAALAC認定
InnoSerはAAALAC認証を取得し、責任ある動物ケアと利用への取り組みを実証しています。AAALAC Internationalは、自主的な認証および評価プログラムを通じて科学における動物の適切な扱いを推進する非営利組織です。InnoSerのオランダおよびベルギー施設は、それぞれ2016年および2020年よりAAALAC認証を取得しています。AAALAC認証プログラムの詳細はこちらをご覧ください。
動物福祉
3R原則は、政策や規制の変更から新技術・手法の開発と普及に至るまで、あらゆる分野に影響を及ぼします。このためInnoSerは、これらのプロセスに対する継続的な取り組みと監視を実施しています。当社が実践する手順は、動物実験の代替・削減・改善を最大限に実現し、研究および医薬品開発におけるこれらの原則への取り組みを促進します。
info@innoserlaboratories.com